190 related articles for article (PubMed ID: 20665504)
1. Bypassing phase 1 trials in the cancer drug development paradigm: generally unwise and potentially dangerous.
Markman M
Cancer; 2010 Nov; 116(22):5116-8. PubMed ID: 20665504
[No Abstract] [Full Text] [Related]
2. Clinical trial design in metastatic breast cancer: a commentary.
Levine M
Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
[TBL] [Abstract][Full Text] [Related]
3. Q&A: Geoffrey Shapiro on phase I drug trials. Spoke with Suzanne Rose.
Shapiro G
Cancer Discov; 2013 Oct; 3(10):1089. PubMed ID: 24124216
[No Abstract] [Full Text] [Related]
4. Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs.
Potter DM
J Biopharm Stat; 2006; 16(5):579-604. PubMed ID: 17037260
[TBL] [Abstract][Full Text] [Related]
5. [Current status and issues in clinical trials of anticancer agents].
Kojima H
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():295-301. PubMed ID: 7986107
[TBL] [Abstract][Full Text] [Related]
6. Review: new biological insights in early clinical studies.
Maur M; Sessa C
Hematol Oncol; 2007 Jun; 25(2):53-7. PubMed ID: 17351979
[TBL] [Abstract][Full Text] [Related]
7. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
[TBL] [Abstract][Full Text] [Related]
8. Shortening the timeline of pediatric phase I trials: the rolling six design.
Skolnik JM; Barrett JS; Jayaraman B; Patel D; Adamson PC
J Clin Oncol; 2008 Jan; 26(2):190-5. PubMed ID: 18182661
[TBL] [Abstract][Full Text] [Related]
9. Anticancer drug development: moving away from the old habits.
Ades F; Zardavas D; Aftimos P; Awada A
Curr Opin Oncol; 2014 May; 26(3):334-9. PubMed ID: 24614094
[No Abstract] [Full Text] [Related]
10. Antimalaria drug offers antitumor strategies.
Hede K
J Natl Cancer Inst; 2011 Oct; 103(20):1490-1. PubMed ID: 21972227
[No Abstract] [Full Text] [Related]
11. [Drug therapy for inoperable gastric cancer: current possibilities and perspectives of development].
Volkov NM; Moiseenko VM
Vopr Onkol; 2007; 53(4):383-92. PubMed ID: 17969398
[No Abstract] [Full Text] [Related]
12. Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy?
Bell IM
J Med Chem; 2004 Apr; 47(8):1869-78. PubMed ID: 15055985
[No Abstract] [Full Text] [Related]
13. 3 + 3 not equal to (Rolling) 6.
Hartford C; Volchenboum SL; Cohn SL
J Clin Oncol; 2008 Jan; 26(2):170-1. PubMed ID: 18182656
[No Abstract] [Full Text] [Related]
14. [Cancer chemotherapy today and in the future].
Tanneberger S
Z Gesamte Inn Med; 1990 Dec; 45(23):693-5. PubMed ID: 2102024
[TBL] [Abstract][Full Text] [Related]
15. Response surface methodology and the design of clinical trials for the evaluation of cancer chemotherapy.
Carter WH
Cancer Treat Rep; 1985 Oct; 69(10):1049-53. PubMed ID: 4042084
[No Abstract] [Full Text] [Related]
16. Food and Drug Administration requirements for approval of new anticancer drugs.
Johnson JR; Temple R
Cancer Treat Rep; 1985 Oct; 69(10):1155-9. PubMed ID: 4042094
[TBL] [Abstract][Full Text] [Related]
17. [Continual reassessment method (CRM)].
Ishizuka N
Gan To Kagaku Ryoho; 2000 Aug; 27(9):1449-57. PubMed ID: 10969605
[TBL] [Abstract][Full Text] [Related]
18. [Development of cancer chemotherapy. The discovery of new active drugs. II].
Lopez M
Clin Ter; 1998; 149(6):453-9. PubMed ID: 10100409
[No Abstract] [Full Text] [Related]
19. Clinical studies with modulators of multidrug resistance.
Fisher GA; Sikic BI
Hematol Oncol Clin North Am; 1995 Apr; 9(2):363-82. PubMed ID: 7642468
[TBL] [Abstract][Full Text] [Related]
20. Phase I cancer trials: therapeutic research?
Wells RJ
Hastings Cent Rep; 2001; 31(1):4; author reply 5. PubMed ID: 11478096
[No Abstract] [Full Text] [Related]
[Next] [New Search]
